Description: Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centred on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.
Home Page: www.inventivapharma.com
IVA Technical Analysis
50 rue de Dijon
Daix,
21121
France
Phone:
33 3 80 44 75 00
Officers
| Name | Title |
|---|---|
| Mr. Frederic Cren | Co-Founder, CEO & Chairman |
| Dr. Pierre Broqua Ph.D. | Co-Founder, Chief Scientific Officer, Deputy CEO & Director |
| Mr. Jean Volatier | Chief Financial Officer |
| Mr. Eric Duranson L.L.M. | Gen. Counsel |
| Ms. Nathalie Harroy | Head of HR |
| Dr. Irena Konstantinova | Head of Biology & Pharmacology |
| Dr. Michael Cooreman | Chief Medical Officer |
| Mr. Jean-Paul Dutertre M.D. | Head of Pharmacovigilance |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.299 |
| Price-to-Sales TTM: | 19.1815 |
| IPO Date: | 2020-07-10 |
| Fiscal Year End: | December |
| Full Time Employees: | 109 |